DBT approves Funding for MRNA-based COVID-19 Vaccine - HGCO19 for Clinical Trials
The Department of Biotechnology (DBT), Ministry of Science & Technology has approved additional funding towards clinical studies of India's 'first of its kind' mRNA-based COVID-19 vaccine - HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd.
- This funding has been awarded under the 'Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission' by DBT's dedicated Mission Implementation Unit at Biotechnology Industry Research Assistance Council (BIRAC) after multiple rounds of evaluation of all the applications that were submitted in response to the 'Request for Expression of Interest (REOI)' under Mission COVID Suraksha for the 'Development of COVID-19 vaccine candidate(s)'.
- DBT has been hand-holding ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 ‘SUJALAM’ Campaign for making more ODF Plus Villages
- 2 Indian Scientists develop Carbon-based Wrapper for preserving Fruits
- 3 Grant-in-aid to Rural Local Bodies
- 4 Project 75 (I): RFP issued for Six Conventional Submarines
- 5 KASEZ: India’s First Green Industrial City”
- 6 e-RUPI: A Digital Payment Solution
- 7 PIB Corner
- 8 PIB Corner
- 9 PIB Corner
- 10 PIB Corner
